Avalon Healthcare Solutions

At Avalon, Women’s History Month provides a valuable opportunity to honor and amplify the journeys and achievements of women worldwide. Throughout March, we reflect on the historical milestones, resilience, and impact of female leaders throughout history. To our partners, clients, and women everywhere, Happy Women’s History Month! #AvalonHCS #WeAreAvalon #WomensHistoryMonth

For non-small cell lung cancer (NSCLC) patients, advancements in medical technology have uniquely positioned laboratory benefit managers to assist health plans in increasing the quality of care, enable providers to utilize broad panel genomic testing and incorporate liquid biomarker testing, and eliminate PA bottlenecks.?? ? In this article, Avalon Vice President of Product Matt Ingram and Avalon Product Manager Dr. Michael Dovidio, PharmD, explore how effective laboratory value management and non-invasive liquid biomarker testing can transform patient care by accelerating patient identification, reducing the need for tissue samples, and minimizing costs.?? ? Read More: https://lnkd.in/gvuVxk2b??? ? #AvalonHCS #Oncology #CancerTreatment #LaboratoryBenefitManagement??

The FDA’s resolution of the tirzepatide shortage marks a turning point in the soaring GLP-1 drug market, but it also raises concerns over affordability, access, and health equity. With compounded alternatives off the table, patients now face steep costs—leaving those without robust insurance coverage struggling to obtain these life-changing medications.? ? In this article, Avalon Vice President of Product Julie Schulz, MD, MPH, and Product Manager Michael Dovidio, PharmD, explore this issue and highlight innovative benefit management approaches that will be essential for balancing cost containment, equitable access, and patient outcomes in the years ahead.? ? Read More: https://lnkd.in/e6i9HBs7?? ? #AvalonHCS #GLP1 #LaboratoryBenefitManagement #HealthcareCosts?

In observance of National Kidney Month, Avalon is joining the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in their efforts to raise awareness of one of the top 10 deadliest conditions affecting Americans. Chronic kidney disease (CKD) often presents progressive and frequently overlooked symptoms that can increase the risk of serious health complications which include heart attacks, strokes, and kidney failure. Sadly, many patients remain unaware of their condition until it has advanced to later stages.? ? CKD affects approximately 37 million people and is a major contributor to healthcare costs for both Medicare and commercial insurers. Learn how Avalon’s Lab Insights can provide health plans with critical lab data that helps slow disease progression and improves care quality: https://lnkd.in/dSUS42pn? ? #AvalonHCS #ChronicKidneyDisease #HealthcareCosts?#NIDDK #KidneyMonth

Avalon is proud to continue our support of the American Heart Association through its signature initiative, Go Red for Women Tampa Bay!? ? Avalonians participated alongside local leaders and donors at the 2025 Tampa Bay Go Red for Women Luncheon, where inspiring survivors of heart disease and stroke shared their impactful stories as national volunteers, encouraging women everywhere to take charge of their health.? ? Join us in our efforts to combat heart disease and stroke: https://lnkd.in/eJvc4aYT?? ? ?? #WeAreAvalon #AvalonHCS #GoRedforWomen???

Did you miss our January Webinar? Tune for insights from Avalon Healthcare Solutions CEO Bill Kerr, MD, MBA, and Maverick Health Policy CEO Julie Barnes, JD, as they explore key trends and challenges that influenced the healthcare industry in 2024, how election-related policy changes may shape the healthcare and lab ecosystem in the coming year, and much more. Access the recording: https://lnkd.in/eRjzSaVW #AvalonHCS #Webinar #LaboratoryBenefitManagement

Recently, Dr. Ben Horton, Avalon Vice President and Senior Medical Director of Physician Review Services participated in an insightful discussion at the Q1 Productions Diagnostic Coverage & Reimbursement Conference.? ? During the conference, Dr. Horton had the opportunity to engage in a fireside chat with Jennifer Fernandez from Caris Life Sciences to discuss the shifts in the constantly evolving regulatory landscape and explore the impact of FDA oversight of laboratory-developed tests (LDTs) into payment frameworks and its implications for reimbursement strategies, the essential need for compliance in precision medicine, and share insights from Avalon's approach to making coverage decisions for laboratory tests.?? ? Did you miss the session? Learn more about Avalon’s approach to these emerging challenges: www.avalonhcs.com?? ? #AvalonHCS #Q1Productions #LaboratoryBenefitManagement?

We are proud to announce that Avalon has once again attained HITRUST r2 Certification for Security and Privacy controls!??? ??? At Avalon, we believe that protecting sensitive healthcare data is not only a priority but a genuine responsibility we embrace on behalf of our trusted partners and clients.??? ??? This achievement places Avalon in an elite group of organizations worldwide and underscores our commitment to meeting demanding regulatory compliance and addressing security and data protection challenges through a comprehensive and flexible framework of prescriptive and scalable security controls.??? ??? Discover how Avalon’s commitment to data security and access to lab data is enabling healthcare insurers to utilize lab values proactively, resulting in improved care, reduced costs, and enhanced clinical outcomes at scale: https://www.avalonhcs.com/??? ?? ?? ?? #AvalonHCS #HITRUST #InformationSecurity??

The FDA’s resolution of the tirzepatide shortage marks a turning point in the soaring GLP-1 drug market, but it also raises concerns over affordability, access, and health equity. With compounded alternatives off the table, patients now face steep costs—leaving those without robust insurance coverage struggling to obtain these life-changing medications.? ? In this article, Avalon Vice President of Product Julie Schulz, MD, MPH, and Product Manager Michael Dovidio, PharmD, explore this issue and highlight innovative benefit management approaches that will be essential for balancing cost containment, equitable access, and patient outcomes in the years ahead.? ? Read More: https://lnkd.in/e6i9HBs7?? ? #AvalonHCS #GLP1 #LaboratoryBenefitManagement #HealthcareCosts?

We’re thrilled to welcome Dr. Kristie Ressler as our new Chief Medical Officer! With over a decade of experience in both clinical practice and healthcare innovation, Dr. Ressler brings a unique blend of medical expertise and business strategy to Avalon. Having practiced as a surgeon, her passion for transforming healthcare delivery has driven her career, from leading physician advisory teams to developing cutting-edge payment policies and clinical solutions. We’re excited for the impact Dr. Ressler will make in shaping Avalon’s clinical strategy and healthcare innovation. Please join us welcoming Dr. Ressler to the Avalon team! #AvalonHCS #WeAreAvalon